We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Show more
Approval is based on the CheckMate-77T trial, in which the Opdivo-based regimen demonstrated significantly longer event-free survival compared to the chemotherapy and placebo arm; a high...
Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies ...
COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies Approval is supported by data from the...
In the Phase 3b/4 PSORIATYK SCALP trial Sotyktu was superior to placebo across all primary and secondary endpoints at Week 16, with patients reporting significantly greater improvement in...
COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies Approval is supported by data from the...
Final results from the DAYBREAK long-term extension study showed brain volume loss decreased during Phase 3 studies and was sustained with continuous Zeposia treatment for up to 5 years More...
These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference At ten years, more than 40% (43%) of...
Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2024 on Thursday, October 31, 2024. Company executives will review financial results and address inquiries from...
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company...
Data from proof-of-concept, randomized, Phase 2 RELATIVITY-104 trial exploring the combination of nivolumab, relatlimab (1:1) and chemotherapy as first-line treatment for stage IV or recurrent...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.1601 | 4.1911136981 | 51.54 | 54.54 | 50.71 | 18007065 | 52.6381929 | CS |
4 | 3.7201 | 7.44317727091 | 49.98 | 54.54 | 47.55 | 12849418 | 50.61968998 | CS |
12 | 12.6601 | 30.8481968811 | 41.04 | 54.54 | 39.925 | 13569087 | 48.03403377 | CS |
26 | 1.7601 | 3.38871775125 | 51.94 | 54.54 | 39.35 | 14222047 | 45.50262347 | CS |
52 | -3.3999 | -5.95429071804 | 57.1 | 57.645 | 39.35 | 14842235 | 48.61735582 | CS |
156 | -5.6899 | -9.58056911938 | 59.39 | 81.435 | 39.35 | 12300620 | 60.37811995 | CS |
260 | 4.0701 | 8.20088656055 | 49.63 | 81.435 | 39.35 | 12469129 | 60.60809764 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions